Emerson C. Perin
Experienced in Mitral Valve Prolapse

Dr. Emerson C. Perin

Cardiology | Interventional Cardiology
6624 Fannin St, Ste 2780-1, 
Houston, TX 
Accepting New Patients
Experienced in Mitral Valve Prolapse
6624 Fannin St, Ste 2780-1, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Emerson Perin, MD, is dedicated to delivering high-quality, compassionate care to Houston and nearby communities. Emerson Perin specializes in Cardiology and works at Texas Heart Medical Group. To make an appointment, please call (713) 790-9401. To review all accepted insurance carriers, please visit: https://www.stlukeshealth.org/patients-visitors/patients/billing-insurance/insurances-accepted.

Dr. Perin is rated as an Experienced provider by MediFind in the treatment of Mitral Valve Prolapse. His top areas of expertise are Coronary Heart Disease, Atherosclerosis, Angina, Bone Marrow Aspiration, and Thrombectomy.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Universidade Federal De Pelotas - Brazil
Specialties
Cardiology
Interventional Cardiology
Licenses
Internal Medicine in TX
Hospital Affiliations
Baylor St. Luke's Medical Center - Houston, TX
Languages Spoken
English
Portuguese
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

The Texas Heart Institute at Baylor College of Medicine
6624 Fannin St, Ste 2780-1, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)
Enrollment Status: Terminated
Publish Date: October 09, 2025
Intervention Type: Genetic, Drug
Study Phase: Phase 3
A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris
A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Biological
Study Drug: Replication-Deficient Adenovirus Vector-Expressing cDNA/Genomic Hybrid VEGF
Study Phase: Phase 1/Phase 2
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Other, Drug
Study Drug: ARRY-371797 (PF-07265803)
Study Phase: Phase 3
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
Enrollment Status: Completed
Publish Date: October 30, 2023
Intervention Type: Device
Study Phase: Not Applicable
The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study
The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Device
Study Phase: Not Applicable
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Enrollment Status: Completed
Publish Date: January 10, 2022
Intervention Type: Biological, Other
Study Phase: Phase 3
Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Enrollment Status: Unknown
Publish Date: November 01, 2019
Intervention Type: Combination product
Study Drug: Human Recombinant Fibroblast Growth Factor-1
Study Phase: Phase 2
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Enrollment Status: Terminated
Publish Date: June 23, 2017
Intervention Type: Device
Study Phase: Phase 3
View 7 Less Clinical Trials

85 Total Publications

Cardiac Progenitor Cells in HLHS: Feasibility Now, Efficacy Next?
Cardiac Progenitor Cells in HLHS: Feasibility Now, Efficacy Next?
Journal: JACC. Heart failure
Published: October 08, 2025
Similar Doctors
Distinguished in Mitral Valve Prolapse
Dr. Dipan Shah
Cardiology
Distinguished in Mitral Valve Prolapse
Dr. Dipan Shah
Cardiology

Houston Methodist Debakey Cardiology Associates

6550 Fannin St Ste 1901, 
Houston, TX 
 (0.6 miles away)
713-441-1100
Languages Spoken:
English
See accepted insurances

Dipan Shah is a Cardiologist in Houston, Texas. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Mitral Valve Prolapse. His top areas of expertise are Aortic Regurgitation, Mitral Valve Regurgitation, Cardiomyopathy, Mitral Valve Prolapse, and Cardiac Ablation.

Distinguished in Mitral Valve Prolapse
Dr. William Zoghbi
Cardiology
Distinguished in Mitral Valve Prolapse
Dr. William Zoghbi
Cardiology

Houston Methodist Debakey Cardiology Associates

6550 Fannin St Ste 1901, 
Houston, TX 
 (0.6 miles away)
713-441-1100
Languages Spoken:
English
See accepted insurances

William Zoghbi is a Cardiologist in Houston, Texas. Dr. Zoghbi is rated as a Distinguished provider by MediFind in the treatment of Mitral Valve Prolapse. His top areas of expertise are Mitral Valve Regurgitation, Aortic Regurgitation, Mitral Valve Prolapse, Mitral Stenosis, and Percutaneous Coronary Intervention (PCI).

Distinguished in Mitral Valve Prolapse
Dr. Kevin Lisman
Cardiology
Distinguished in Mitral Valve Prolapse
Dr. Kevin Lisman
Cardiology

Office

6400 Fannin St, 
Houston,, TX 
 (1.1 miles away)
713-790-0841
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Lisman is a Cardiologist in Houston,, Texas. Dr. Lisman is rated as a Distinguished provider by MediFind in the treatment of Mitral Valve Prolapse. His top areas of expertise are Prinzmetal's Variant Angina, Coronary Artery Spasm, Metabolic Syndrome, Pacemaker Implantation, and Heart Bypass Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Perin's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile